8:30 am Chair’s Opening Remarks

9:00 am Industrialising Cell Therapies: Managing Complexity Across the Ecosystem

9:30 am Late Breaking Abstracts

10:00 am CAR-TCR Landscape Review

10:30 am Morning Refreshments & Tech slam

Translation
Track

Manufacturing
Track

Development & Commercialisation Track

Translating Effective Allogeneic Therapies

Technology Transfer

 

Market Access Innovations for CAR-T Therapies

11.30 Human Vd1+ T Cells; an Allogeneic ‘Off-the-Shelf’ T Cell Therapy Platform

Alice Brown, VP, Research and Gene Engineering, GammaDelta Therapeutics

Click here to see the Event Guide for more information

11.30 Challenges Carrying Out Tech Transfer for Manufacturing Sites

Therese Solstad Saunders, Senior Adviser, Norwegian Medicines Agency

Click here to see the Event Guide for more information

11.30 Development and Execution of Clinical Trials in Europe

Helen-Tayton Martin, CBO, Adaptimmune

Click here to see the Event Guide for more information

 

 

 

 

 

 

 

 

 

 

 

12:30 Exploiting NK Cell Receptors for Autologous and Allogeneic CAR T Cell Therapy

Peggy Sotiropoulou, Director, Research & Development, Celyad

Click here to see the Event Guide for more information

12:00 Streamlining CAR-T Discovery and Lentiviral
Manufacture for Cell and Gene Therapies

Ryan Cawood, CEO, Oxgene

Click here to see the Event Guide for more information

12:30 Process Intensification and Technology Development for CAR-T therapies

Qasim Rafiq, Associate Professor, Cell & Gene Therapy Bioprocessing, University College London

Click here to see the Event Guide for more information

12:00 Crossing borders: Supply Chain Strategies That Foster Sustainability in a Rapidly Advancing International Environment

Mark Flower, VP, Business Development, Be The Match BioTherapies®

Click here to see the Event Guide for more information

12:30 Overcoming Cross-border Restrictions for Access

Annie Hubert, Senior Director, Section & Public Policy, Alliance for Regenerative Medicine

Click here to see the Event Guide for more information

Translation Track

Translating Effective Allogeneic Therapies

11.30 Human Vd1+ T Cells; an Allogeneic ‘Off-the-Shelf’ T Cell Therapy Platform
• Exploring strategies to use the unique properties of Vd1 gd T cells to:
• Generate an allogeneic platform for the treatment of solid tumours and hematologic malignancies
• Improve the tumour targeting and safety profile of engineered cell therapies

Alice Brown, VP, Research and Gene Engineering, GammaDelta Therapeutics


12:00 Exploiting NK Cell Receptors for Autologous and Allogeneic CAR T Cell Therapy
• Targeting hematopoietic and solid malignancies with NKG2D-based CAR T cells

• Development of non-gene edited allogeneic CAR T cells

• Efficacy and safety of autologous and allogeneic CAR T cells targeting solid tumours

Peggy Sotiropoulou, Director, Research & Development, Celyad

Manufacturing Track

Technology Transfer

11.30 Challenges Carrying Out Tech Transfer for Manufacturing Sites
• Experience managing different raw materials which require different supply agreements and approval status

• Introduction to the GMP requirements for the EU region to avoid challenges moving cross-country

• Managing process changes without impacting the product quality and different product

Therese Solstad Saunders, Senior Adviser, Norwegian Medicines Agency


12:00 Round Table Discussion: Logistical Challenges Transporting CAR-TCR Products to Sites Internationall

• How to maintain starting material quality in a timely manner?

• Challenges in customer screening in transportation

• Outline pros and cons of coaching containers and preference for shipping materials

• Should companies compromise own practice to find a way that works with transport service providers?

Development & Commercialisation Track

Market Access Innovations for CAR-T Therapies

11.30 Development and Execution of Clinical Trials in Europe


12:00 Overcoming Cross-border Restrictions for Access
• Describe cross-border challenges for patients without central funding, creating an untimely process

• Expanding centres across Europe to overcome the geographical access challenges

Annie Hubert, Senior Director, Section & Public Policy, Alliance for Regenerative Medicine

Helen-Tayton Martin, CBO, Adaptimmune

 

1:00 pm Lunch & Networking

14:00 Panel Discussion: Review Cell Sources to Optimise Cell Functionality and Persistence

Cedrik Britten, VP, Oncology Cell Therapy Research Unit, GlaxoSmithKline

David Gilham, VP, Research & Development, Celyad

Blake Aftab, VP, Head of Preclinical & Translational Sciences, Atara Biotherapeutics

Click here to see the Event Guide for more information

14:00 Panel Discussion: How to Improve Process Development for CAR-TCR Cell Manufacturing

Michal Besser, Head of Laboratory, Director, Sheba Medical Center

Click here to see the Event Guide for more information

14:00 Panel Discussion: How Does the Lack of a Cantralised Process in Europe Impact Clinical Development?AutolusNovartis

Annie Hubert, Senior Director, Section & Public Policy, Alliance for Regenerative Medicine

Vicki Coutinho, Head of Global Regulatory Affairs, Autolus

Oezlem Anak, VP & Senior Global Head of Clinical Program,
Novartis

Click here to see the Event Guide for more information

15:00 Development of an Allogeneic, Off-the-Shelf T-cell Immunotherapy Cell Therapies and Derivation of a Next-Generation CAR-T Platform

Blake Aftab, VP, Head of Preclinical & Translational Sciences, Atara Biotherapeutics

Click here to see the Event Guide for more information

Cell Characterisation

15.00 Leveraging High-Dimensional '-omics'
Technologies for Comprehensive Profiling of CAR T cells
to Resolve Drug Product Complexity

Eric Alonzo, Senior Scientist, Cell Analytics, bluebird bio

Click here to see the Event Guide for more information

15:00 IP and Legal Implications for CAR-TCR Therapies 

Lisa Kinsella, Head Legal NTO, Biologics, Cell & Gene,
Novartis

Stefan Ibing, Attorney at Law, Head of Legal NPhS, Novartis

Click here to see the Event Guide for more information

Translation Track

Translating Effective Allogeneic Therapies

14:00 Panel Discussion: Review Cell Sources to Optimise Cell Functionality and Persistence

  • Discuss the strengths and weaknesses of TILs, nonengineered T cells and iPSC cells
  • What is the best cell source for sustainability in autologous and allogeneic therapies?

Cedrik Britten, VP, Oncology Cell Therapy Research Unit, GlaxoSmithKline

David Gilham, VP, Research & Development, Celyad

Blake Aftab, VP, Head of Preclinical & Translational Sciences, Atara Biotherapeutics


15:00 Development of an Allogeneic, Off-the-Shelf T-cell Immunotherapy Cell Therapies and Derivation of a Next-Generation CAR-T Platform

  • Clinical development of allogeneic off-the-shelf T cell immunotherapies in oncology and autoimmune disease
  • Clinical and translational studies provide insight into functional biomarkers correlating to efficacy and in vivo expansion
  • Applying clinical and translational findings to the development of next gen allogeneic off-the-shelf CAR-T cell therapies

Blake Aftab, VP, Head of Preclinical & Translational Sciences, Atara Biotherapeutics

Manufacturing Track

Technology Transfer

14:00 Process Intensification and Technology Development for CAR-T therapies

  • Establishing a process control strategy facilitates process intensification, increasing yield and efficiency
  •  Automated strategies for process and product development enables increased consistency
  • Improved control allows for the potential of patient-specific adaptive manufacturing

Qasim Rafiq, Associate Professor, Cell & Gene Therapy Bioprocessing, University College London


Cell Characterisation


15.00 CAR-T Product Characterisation & Function • Gain clarity on product composition, stability and characterisation

  •  Define what makes a cell sample not possible to manufacture for CAR-T • Discuss key biomarkers to predict patient response • Identify cellular functions which categorise subpopulations as less beneficial
  • Explore cell recovery post cryopreservation, review techniques and buffers which maintain cell function

Development & Commercialisation Track

Market Access Innovations for CAR-T Therapies

14:00 Panel Discussion: How Does the Lack of a Cantralised Process in Europe Impact Clinical Development?

  • Compare how the EMA regulatory requirements compare to the FDA
  • Discuss the need for a harmonised approach in Europe to improve patient access

Annie Hubert, Senior Director, Section & Public Policy, Alliance for Regenerative Medicine


15:00 IP and Legal Implications for CAR-TCR Therapies 

  • Clarifying IP requirements for novel therapies
  • Considerations for developing CAR-TCR therapies in a crowded market

3:30 pm Close of the Summit